Grace Therapeutics, Inc. (GRCE) - Q2 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. Grace Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug delivery technologies for rare and orphan diseases. The company is currently prioritizing its lead candidate, GTx-104 (an injectable nimodipine formulation for aneurysmal subarachnoid hemorrhage), following a strategic realignment that deprioritized other pipeline assets.
Key Financial Metrics
| Metric (in thousands, except per share) | Q2 2026 | Q2 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(15,790) | $(3,362) |
| Loss Per Share (Basic & Diluted) | $(0.91) | $(0.21) |
| Cash and Cash Equivalents (End of Period) | $13,756 | $20,005 |
| Net Cash Used in Operating Activities | $(3,221) | $(1,801) |
| Total Assets | $50,073 | $66,654 |
| Total Liabilities | $1,862 | $2,758 |
Note: The company reported no revenue for the period. Operating expenses were dominated by a non-cash impairment charge.
Material Changes vs. Prior Period
- Significant Impairment Charge: The company recorded a $13.5 million impairment of intangible assets (In-Process Research and Development) related to drug candidates GTx-102 and GTx-101. This decision followed a strategic review to focus resources exclusively on GTx-104.
- Increased Net Loss: Net loss increased by approximately $12.4 million compared to the prior year quarter, primarily driven by the impairment charge.
- Reduced Operating Expenses: Excluding the impairment, operating expenses decreased. Research and Development (R&D) expenses fell by $258,000 to $697,000, and General and Administrative (G&A) expenses fell by $448,000 to $1.687 million, reflecting workforce reductions and the completion of the Phase 3 STRIVE-ON trial.
- Regulatory Status: In April 2026, the FDA issued a Complete Response Letter (CRL) regarding the NDA for GTx-104. The CRL cited Chemistry, Manufacturing, and Controls (CMC) issues and non-clinical data requirements but did not identify clinical safety or efficacy deficiencies.
Guidance, Outlook, and Risks
- Regulatory Path Forward: Management plans to resubmit the NDA for GTx-104 after addressing CRL items. This includes a dual-source manufacturing strategy, involving a technology transfer to a second U.S.-based contract manufacturer to mitigate cGMP compliance risks at the current facility.
- Liquidity and Financing: As of June 30, 2026, cash balances were $13.8 million. However, in a subsequent event in August 2026, the company completed a private placement raising approximately $9.1 million. Management believes total cash resources will sustain operations through at least the end of calendar 2028.
- Key Risks:
- Failure to successfully address FDA CRL items or obtain approval for GTx-104.
- Dependence on third-party contract manufacturers for cGMP compliance.
- Need for additional capital beyond 2028 to fund commercialization or further development.
- Uncertainty regarding the commercialization or licensing of deprioritized assets (GTx-101, GTx-102).
Investor Verification Checklist
- Manufacturing Remediation: Verify the progress of the technology transfer to the new U.S.-based contract manufacturer and the status of the current manufacturer's cGMP remediation.
- NDA Resubmission Timeline: Confirm the expected date for resubmitting the GTx-104 NDA and the FDA's projected review timeline.
- Cash Runway: Re-evaluate the operating runway post-August 2026 financing to confirm the "through end of 2028" projection holds against actual burn rates.
- Pipeline Monetization: Monitor for any announcements regarding the licensing or sale of GTx-101 and GTx-102, as internal development has ceased.
- Stock Dilution: Review the impact of the August 2026 private placement (4.76 million shares issued) on existing shareholder equity.